Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.80 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | POLA1 | P09884 | 1/20 | 0.59 |
| ▸ | POLG | P54098 | 1/20 | 0.59 |
| ▸ | FAP | Q12884 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.58 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97302 | 0.89 | FGFR1 (1.00) | FGFR1SLC22A6CYP2D6CYP3A4 | |
| SCHEMBL12875233 | 0.88 | FGFR1 (0.78) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL29258953 | 0.87 | FGFR1 (0.77) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL20644336 | 0.86 | FGFR1 (0.73) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL16020629 | 0.85 | FGFR1 (0.93) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL20644337 | 0.85 | FGFR1 (0.68) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL20644448 | 0.85 | FGFR1 (0.85) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL16063254 | 0.84 | FGFR1 (0.68) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL12391574 | 0.84 | FGFR1 (0.68) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL16063265 | 0.84 | FGFR1 (0.68) | FGFR1SLC22A6ABCB11POLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309565-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120058975-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-03-08 | — | — | US | disclosed |
| US-8008308-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-30 | — | — | US | disclosed |
| US-20110015149-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | CHIMERIX, INC. | 2011-01-20 | — | — | US | disclosed |
| US-7790703-B2 | New phosphonate ester derivatives of purine or pyrimidine antivirals; side effect reduction, less toxic, bioavailability | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100173870-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-07-08 | — | — | US | disclosed |
| US-7687480-B2 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-30 | — | — | US | disclosed |
| US-7452898-B2 | Use of 1-O-octadecylpropanediol-3-cidofovir to treat viral diseases such as HIV, influenza, herpes virus, cytomegalovirus, hepatitis virus, Epstein-Barr virus, varicella zoster virus, orthopox virus, ebola virus and papilloma virus | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080103115-A1 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103115-A1 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | APRT, AASDHPPT, APOBEC3G | FGFR1 2772/4885SLC22A6 1664/4885ABCB11 2912/4885 |
| US-20110015149-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | ACE, CYP27A1, LIPC | FGFR1 3111/4885SLC22A6 534/4885ABCB11 154/4885 |
| US-20120058975-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | FGFR1 1716/4885SLC22A6 903/4885ABCB11 1882/4885 |
| US-20100173870-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | FGFR1 1716/4885SLC22A6 903/4885ABCB11 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.